company background image
2L9 logo

Blueprint Medicines DB:2L9 Stock Report

Last Price

€86.50

Market Cap

€5.4b

7D

7.5%

1Y

111.0%

Updated

28 Mar, 2024

Data

Company Financials +

Blueprint Medicines Corporation

DB:2L9 Stock Report

Market Cap: €5.4b

2L9 Stock Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.

2L9 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Blueprint Medicines Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Blueprint Medicines
Historical stock prices
Current Share PriceUS$86.50
52 Week HighUS$94.00
52 Week LowUS$38.00
Beta0.63
1 Month Change-4.95%
3 Month Change2.98%
1 Year Change111.03%
3 Year Change3.87%
5 Year Change27.68%
Change since IPO235.01%

Recent News & Updates

Recent updates

Shareholder Returns

2L9DE BiotechsDE Market
7D7.5%1.0%1.8%
1Y111.0%33.7%5.7%

Return vs Industry: 2L9 exceeded the German Biotechs industry which returned 34.7% over the past year.

Return vs Market: 2L9 exceeded the German Market which returned 7% over the past year.

Price Volatility

Is 2L9's price volatile compared to industry and market?
2L9 volatility
2L9 Average Weekly Movement9.8%
Biotechs Industry Average Movement5.7%
Market Average Movement4.8%
10% most volatile stocks in DE Market9.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2L9 has not had significant price volatility in the past 3 months.

Volatility Over Time: 2L9's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2008655Kate Havilandhttps://www.blueprintmedicines.com

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.

Blueprint Medicines Corporation Fundamentals Summary

How do Blueprint Medicines's earnings and revenue compare to its market cap?
2L9 fundamental statistics
Market cap€5.38b
Earnings (TTM)-€469.97m
Revenue (TTM)€231.18m

23.3x

P/S Ratio

-11.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2L9 income statement (TTM)
RevenueUS$249.38m
Cost of RevenueUS$12.80m
Gross ProfitUS$236.58m
Other ExpensesUS$743.57m
Earnings-US$506.98m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-8.28
Gross Margin94.87%
Net Profit Margin-203.30%
Debt/Equity Ratio521.0%

How did 2L9 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.